Aurobindo Pharma arm’s injectable facility gets product nod from U.S. FDA
A new injectable facility of Aurobindo Pharma’s subsidiary Eugia Steriles has received its first product approval from the United States Food and Drug Administration.
The U.S. FDA inspected the unit in Parawada mandal of Anakapalli district, Andhra Pradesh, from March 28 to April 5. It has now received its first product approval from the U.S. FDA for Lidocaine Hydrochloride Injection, USP, 1% (10 mg/mL) and 2% (20 mg/mL).
The sANDA (supplemental abbreviated new drug application) was submitted as Prior Approval Supplement for addition of an alternate drug product manufacturing, labelling, packaging and testing facility, Aurobindo Pharma said in a filing on Wednesday.
Published - September 11, 2024 01:46 pm IST
Disclaimer: The copyright of this article belongs to the original
author. Reposting this article is solely for the purpose of information
dissemination and does not constitute any investment advice. If there is
any infringement, please contact us immediately. We will make
corrections or deletions as necessary. Thank you.